NEW: No-Cost Streetwise Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

The Life Sciences Report


With one quarter in the books, are the biotech companies that made The Life Sciences Report Watchlist 2013 meeting expectations? The Watchlist was built on the opinions of experts with experience in the space. The company stats as of April 22, along with those of leading biotech indices, are tabulated below.

Analyst Company Market Cap
M = Million
B = Billion
Year to Date
(as of 4/22/13)
Raghuram “Ram” Selvaraju
Managing Director and Head of Healthcare Equity Research
Aegis Capital
Ariad Pharmaceuticals Inc. (ARIA:NASDAQ)

Amarin Corporation plc (AMRN:NASDAQ)

Medivation Inc. (MDVN:NASDAQ)

Trius Therapeutics Inc. (TSRX:NASDAQ)






John McCamant
Medical Technology Stock Letter
Sangamo BioSciences Inc. (SGMO:NASDAQ)

Pharmacyclics Inc. (PCYC:NASDAQ)


Mike King
Senior Analyst & Managing Director
JMP Securities
Navidea Biopharmaceuticals Inc. (NAVB:NYSE)

Celsion Corp. (CLSN:NASDAQ)

Onyx Pharmaceuticals Inc. (ONXX:NASDAQ)

Sarepta Therapeutics Inc. (SRPT:NASDAQ)






Lisa Bayko
JMP Securities
Hyperion Therapeutics Inc. (HPTX:NASDAQ) $396.5M +115.4%
George Zavoico
Senior Biotechnology Analyst
MLV & Co.
Prana Biotechnology Ltd. (PRAN:NASDAQ)

Peregrine Pharmaceuticals (PPHM:NASDAQ)


Mara Goldstein
Senior Biotechnology Analyst
Cantor Fitzgerald
Celldex Therapeutics Inc. (CLDX:NASDAQ)

Galena Biopharma Inc. (GALE:NASDAQ)

Celgene Corp. (CELG:NASDAQ)

NewLink Genetics Corp. (NLNK:NASDAQ)






NYSEArca Biotechnology (BTK) 26.6% year to date
NASDAQ Biotechnology (NBI) 26.9% year to date
George S. Mack, The Life Sciences Report